



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/825,920	04/03/2001	Ronald G. Udell	40524-SGTI	3656
------------	------------	-----------------	------------	------

25763	7590	11/30/2006
-------	------	------------

DORSEY & WHITNEY LLP
INTELLECTUAL PROPERTY DEPARTMENT
SUITE 1500
50 SOUTH SIXTH STREET
MINNEAPOLIS, MN 55402-1498

EXAMINER

WINSTON, RANDALL O

ART UNIT	PAPER NUMBER
----------	--------------

1655

DATE MAILED: 11/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/825,920

Applicant(s)

UDELL ET AL.

Examiner

Randall Winston

Art Unit

1655

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09/15/2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 19-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 19-31 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 0506
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Art Unit: 1655

DETAILED ACTION

Acknowledgement is made of receipt and entry of the amendment filed on September 15, 2006.

Claims 19-31 are under examination.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 19, 23-25 and 27-31 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Matsuyama (US 6485760) in view of White (US 5431916) and Mcpeak (US 6303586).

Applicant argues White, a secondary reference, fails to remedy the deficiencies of Matsuyama because White generically discloses the use of soft gelatin capsules with pharmaceuticals. Therefore, neither reference, alone or in combination, teach or suggest, provide any motivation or an expectation of success to one having ordinary skill in the art that unitary soft gel capsule that encapsulates liquified corosolic acid suitable for oral administration could be prepared by heating rice bran oil, adding a filler, adding the herb, i.e., corosolic acid, and the mixture into soft gel capsule.

Applicant's argument is not found persuasive because as examiner explained in his non-final office action of 05/16/2006, all of the combined references, alone or in

Art Unit: 1655

combination, teach or suggest, provide a motivation or an expectation of creating the claimed invention. For example, Matsuyama teaches an oral composition comprising corosolic acid for an increase in or lowering of blood sugar levels in a patient.

Matsuyama teaches that corosolic acid can be encapsulated (see, column 5, lines 17) but does not specifically teach using a unitary soft gel capsule. Matsuyama also does not expressly teach including rice bran oil in the composition or the claimed amounts administered to a human. However, although Matsuyama does not specifically teach using a unitary soft gel capsule, White remedy that deficiency because White beneficially teaches (see, e.g. column 1 lines 17-41) that soft gelatin capsules containing pharmaceutical actives provide an excellent delivery of pharmaceutical actives because they are the preferred form for accurate and uniform delivery of pharmaceutical actives as well as they are convenient, portable and easy to swallow. The gel capsules can be seamless (i.e. unitary) and beneficially contain fillers to aid in producing an appealing final product. (see, e.g. column 6, lines 25-35 and column 9, lines 53-end). Furthermore, Mcpeak et al. beneficially teach rice bran oil (i.e. the rice bran is in liquid form) to control blood glucose levels. (see, e.g., column 7 lines 52-56). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify Matsuyama's oral composition teachings to include White's beneficial oral unitary soft gel teachings (e.g. it is beneficial to utilize a unitary soft gel capsule because they are the preferred form for accurate and uniform delivery of pharmaceutical actives as well as they are convenient, portable and easy to swallow and also to beneficially include fillers with an unitary gel capsule to produce an

Art Unit: 1655

appealing final product) and also to include the beneficial teachings as taught by Mcpeak's active ingredient which is being utilized for the maintaining or lowering of blood glucose levels in humans to obtain an improved claimed unitary soft gel capsule composition for the oral administration of corosolic acid and rice bran oil in a unitary soft gel capsule for the maintaining or lowering blood sugar levels in humans. The adjustment of other conventional working conditions (e.g. the amount of corosolic acid contained within the unitary soft gel capsule), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made, especially in the absence of evidence to the contrary.

Please Note that patentability of a product (i.e. the claimed unitary soft gel capsule) does not depend upon its method of production (i.e. heating the rice bran oil, continuously stirring the mixture, the corosolic acid is under a vacuum, the mixture is blended with nitrogen, the corosolic acid is produced by 1% Corosolic acid alcohol extracted from *Lagerstroemia Speciosa L.*). If the product in the product-by-process claim is the same as or obvious from a product of the prior art, then the claim is unpatentable even though the prior art product was made by a different process" (see, e.g. MPEP 2113).

Art Unit: 1655

Claims 20-22 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Matsuyama (US 6495760) in view of White (US 5431916), Mcpeak (US 6303586) as applied to claims 19, 23-25 and 27-31 above and further in view of Walter (US 368088), Dickinson (US 3665009) and LaGrone (US 6407068).

Applicant argues, neither reference, alone or in combination, teach or suggest, provide any motivation or an expectation of success to one having ordinary skill in the art that unitary soft gel capsule that encapsulates liquified corosolic acid suitable for oral administration could be prepared by heating rice bran oil, adding a filler such as bees wax, adding the herb, i.e., corosolic acid, and encapsulating the mixture into a soft gel capsule.

Applicant's argument is not found persuasive because as examiner explained in his non-final office action of 05/16/2006, all of the combined references, alone or in combination, teach or suggest, provide a motivation or an expectation of creating the claimed invention. For example, the combined references of Matsuyama, White and Mcpeak teach an improved claimed composition comprising corosolic and rice bran oil contained within an unitary soft gel capsule for maintaining of lowering blood sugar levels in human but the combined references of Matsuyama, White and Mcpeak, do not teach the inclusion of silica and the filler yellow bee's wax in a mixture of the claimed amounts contained within the claimed unitary soft gel composition. However, Walter and Dickinson remedy the deficiency because Walter (see, e.g. example 3) and Dickinson

Art Unit: 1655

(see, e.g. column 5 line 57 and column 6 lines 1-9) beneficially teach it is beneficial to prepare soft gel capsules to aid in oral administration by filling the soft gel capsules with yellow bee's wax and/or bee's wax. Furthermore, LaGrone beneficially teach silica for the prevention of diabetes whereas silica would intrinsically control blood glucose levels when preventing diabetes. (see, e.g., column 4 lines 11-14). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify Matsuyama's oral composition teachings to include White's beneficial oral unitary soft gel teachings (e.g. it is beneficial to utilize an unitary soft gel capsule because they are the preferred form for accurate and uniform delivery of pharmaceutical actives as well as they are convenient, portable and easy to swallow) (and also please note: the yellow bees wax as taught by both Walter and Dickinson can be utilized as a filler within the claimed unitary soft gel capsule to aid in oral administration of the unitary soft gel capsule) and also to include other beneficial teachings taught by Mcpeak and LaGrone whereas Mcpeak and LaGrone's active ingredients are each being utilized for the maintaining or lowering of blood glucose levels in humans to obtain an improved claimed unitary soft gel capsule composition for the oral administration of corosolic acid, rice bran oil, silica and yellow bee's wax in an unitary soft gel capsule for the maintaining or lowering blood sugar levels in humans. The adjustment of other conventional working conditions (e.g. the amount of corosolic acid contained within the soft gel capsule), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

Art Unit: 1655

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made, especially in the absence of evidence to the contrary.

Claim 26 stands rejected under 35 U.S.C. 103(a) as being unpatentable over Matsuyama (US 6485760) in view of White (US 5431916), Mcpeak (US 6303586), Walter (US 368088), Dickinson (US 3665009) and LaGrone (US 6407068) as applied to claims 19-25 and 27-30 in further view of Shanmuyasundam et al. (US 5980902).

Applicant argues, neither reference, alone or in combination, teach or suggest, provide any motivation or an expectation of success to one having ordinary skill in the art that unitary soft gel capsule that encapsulates liquified corosolic acid suitable for oral administration could be prepared by heating rice bran oil, adding a filler such as bees wax, adding the herb, i.e., corosolic acid and *Gymnema sylvestre*, and encapsulating the mixture into an unitary soft gel capsule.

Applicant's argument is not found persuasive because as examiner explained in his non-final office action of 05/16/2006, all of the combined references, alone or in combination, teach or suggest, provide a motivation or an expectation of creating the claimed invention. For example, the combined references of Matsuyama, White, Mcpeak, Walter, Dickinson and LaGrone teach an improved claimed composition comprising corosolic acid, rice bran oil, the filler yellow bee's wax and silica contained

Art Unit: 1655

within an unitary soft gel capsule for maintaining or lowering blood sugar levels in humans but the combined references of Matsuyama, White, Mcpeak, Walter, Dickinson and Lado do not teach the inclusion of an extract of *Gymnema sylvestre* in a mixture of the claimed amounts contained within the claimed unitary soft gel composition.

However, Shanmyasundam remedies the deficiency because Shanmyasundam et al. beneficially teach an extract of *Gymnema sylvestre* for controlling blood sugar to prevent obesity. (see, e.g. column 3 lines 16-20). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify Matsuyama's oral composition teachings to include White's beneficial oral unitary soft gel teachings (e.g. it is beneficial to utilize an unitary soft gel capsule because they are the preferred form for accurate and uniform delivery of pharmaceutical actives as well as they are convenient, portable and easy to swallow) (and also please note: the yellow bees wax as taught by both Walter and Dickinson can be utilized as a filler within the claimed unitary soft gel capsule to aid in oral administration of the unitary soft gel capsule) and also to include other beneficial teachings taught by Mcpeak, LaGrone and Shanmyasundam whereas Mcpeak, LaGrone and Shanmyasundam's active ingredients are each being utilized for the maintaining or lowering of blood glucose levels in humans to obtain an improved claimed unitary soft gel capsule composition for the oral administration of corosolic acid, rice bran oil, silica yellow bee's wax and an extract of *Gymnema sylvestre* in an unitary soft gel capsule for the maintaining or lowering blood sugar levels in humans. The adjustment of other conventional working conditions (e.g. the amount of corosolic acid contained within the soft gel capsule), is deemed merely a

Art Unit: 1655

matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

Accordingly, the claimed invention was prima facie obvious to one of ordinary skill in the art at the time the invention was made, especially in the absence of evidence to the contrary.

No claims are allowed.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Art Unit: 1655

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Randall Winston whose telephone number is 571-272-0972. The examiner can normally be reached on 8AM-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S. Hoffman
11-21-06

SUSAN COE HOFFMAN
PRIMARY EXAMINER